CytomX Therapeutics Inc [CTMX] stock is trading at $1.86, down -19.48%. An important factor to consider is whether the stock is rising or falling in short-term value. The CTMX shares have lost -21.52% over the last week, with a monthly amount drifted -22.18%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
CytomX Therapeutics Inc [NASDAQ: CTMX] stock has seen the most recent analyst activity on July 31, 2025, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $7. Previously, H.C. Wainwright upgraded its rating to Buy on May 15, 2025, and kept the price target unchanged to $5. Piper Sandler upgraded its rating to a Overweight and increased its price target to $3.50 on May 28, 2024. Wedbush upgraded its rating to a Outperform but $8 remained the price target by the analyst firm on May 09, 2024. Jefferies upgraded its rating to Buy for this stock on May 06, 2024, and upped its price target to $8. In a note dated April 22, 2024, JP Morgan upgraded an Neutral rating on this stock.
CytomX Therapeutics Inc [CTMX] stock has fluctuated between $0.40 and $3.10 over the past year. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. CytomX Therapeutics Inc [NASDAQ: CTMX] shares were valued at $1.86 at the most recent close of the market. An investor can expect a potential return of 276.34% based on the average CTMX price forecast.
Analyzing the CTMX fundamentals
CytomX Therapeutics Inc [NASDAQ:CTMX] reported sales of 141.10M for the trailing twelve months, which represents a drop of -25.71%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 0.24%, Pretax Profit Margin comes in at 0.28%, and Net Profit Margin reading is 0.28%. To continue investigating profitability, this company’s Return on Assets is posted at 0.42, Equity is -5.53 and Total Capital is 0.74. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.33.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.71 points at the first support level, and at 1.55 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.14, and for the 2nd resistance point, it is at 2.42.
Ratios To Look Out For
For context, CytomX Therapeutics Inc’s Current Ratio is 4.20. On the other hand, the Quick Ratio is 4.20, and the Cash Ratio is 0.95. Considering the valuation of this stock, the price to sales ratio is 2.17, the price to book ratio is 2.56 and price to earnings (TTM) ratio is 3.25.
Transactions by insiders
Recent insider trading involved Ogden Christopher, Chief Financial Officer, that happened on Jun 16 ’25 when 10614.0 shares were sold. Chief Financial Officer, Ogden Christopher completed a deal on Jun 13 ’25 to sell 1641.0 shares. Meanwhile, SVP, Chief Scientific Officer BELVIN MARCIA sold 13884.0 shares on Jun 16 ’25.
